...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: I think one major reason that,

The phase 2 data is derived from a small patient group. Phase 3 (BOM) data is from a much larger patient group and all patients with diabetes. Perhaps FDA felt that may get different results.

Koo

Share
New Message
Please login to post a reply